Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

The cost of drug development is dropping as AI finds candidates.

Enveda, a biotech startup specializing in AI-driven drug discovery from natural sources, has successfully raised $311 million in a Series E funding round, achieving a valuation of $2 billion. This latest funding, spearheaded by Catalio Capital Management with contributions from Iconiq and other investors, represents a doubling of the company's valuation from the previous year. Founded in 2019 by Viswa Colluru, formerly of Recursion Pharmaceuticals, Enveda aims to accelerate the identification of novel medicines derived from plants and microbes, contrasting with traditional synthetic drug development. The company is actively progressing several AI-discovered drug candidates into human clinical trials. Among these are treatments for severe skin conditions and agents designed to support weight maintenance post-GLP-1 therapy. Although no AI-discovered drugs have yet received FDA approval, Enveda is part of a growing cohort of companies advancing such candidates through the rigorous trial process.

This substantial funding round underscores the increasing investor confidence in AI's capability to revolutionize drug discovery, particularly by tapping into the vast, underexplored chemical diversity of natural products. Enveda's success signals a potential shift in pharmaceutical R&D, moving towards more sustainable and potentially more effective therapeutic avenues by leveraging AI to analyze complex biological data from natural sources.

The advancement of Enveda's candidates into clinical trials is a critical milestone, moving beyond theoretical AI application to real-world efficacy testing. This validates the AI-first approach for natural product drug discovery and suggests that AI-derived medicines may soon enter the regulatory pipeline, potentially reshaping the competitive landscape for both traditional pharmaceutical giants and emerging biotech firms.